~~<i id='2145B470CA'><strike id='2145B470CA'><tt id='2145B470CA'><pre id='2145B470CA'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：explore 2025-10-01 05:39:11 - browse：2863

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Eli Lilly said Tuesday that it will purchase DICE Therapeutics, a small company developing an experimental pill to treat psoriasis, for $2.4 billion in cash.

The deal price of $48 per share represents a 42% premium to DICE’s closing price Friday.

“In combination with its novel technology and expertise in drug discovery, DICE’s talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating autoimmune diseases,” Patrik Jonsson, executive vice president, president of Lilly Immunology and Lilly USA, chief customer officer, said in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： PEPFAR is under serious threat — and so is global health

leisure time

knowledge

entertainment

explore

entertainment

explore

JoeRaedle/GettyImagesThestatisticsaredismal,thoughtheybearrepeating:81%ofoverdosedeathsintheU.S.in20

WSS

Restaurant meals are packed with calories, and we still keep eating them

IRA could hurt research into orphan drugs for rare diseases

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

FDA approves updated Covid vaccines

Tuberculosis patients need more than just free medication

PEPFAR is under serious threat — and so is global health

focus

fashion

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

It was time to plan for my old age. If only I could stop crying

How one medical school became remarkably diverse

How to make the FDA’s new prescription one

Hepatitis C has a cure — but many Americans still lack access to it

What to make of Biden’s latest efforts on cancer research

ChatGPT in medicine: STAT answers readers' burning questions

FDA approves updated Covid vaccines

As demand for Covid shots wanes, Moderna seeks its next success

Judge in Trump's classified documents case questions use of out

knowledge

Sage considers ways to reduce costs following FDA rejection

Will the IRA bring competition to the biologics market?

How CRISPR works, explained in two minutes

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

White House touts steps to stem shortages of cancer treatments

Trump used to be more articulate. What could explain the change?

entertainment

explore

entertainment

explore